AU2013221230A1 - Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients - Google Patents

Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients Download PDF

Info

Publication number
AU2013221230A1
AU2013221230A1 AU2013221230A AU2013221230A AU2013221230A1 AU 2013221230 A1 AU2013221230 A1 AU 2013221230A1 AU 2013221230 A AU2013221230 A AU 2013221230A AU 2013221230 A AU2013221230 A AU 2013221230A AU 2013221230 A1 AU2013221230 A1 AU 2013221230A1
Authority
AU
Australia
Prior art keywords
patient
viral
infection
sialidase
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013221230A
Other languages
English (en)
Inventor
Tiejun Li
Ron Moss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of AU2013221230A1 publication Critical patent/AU2013221230A1/en
Priority to AU2017258955A priority Critical patent/AU2017258955A1/en
Priority to AU2019226190A priority patent/AU2019226190B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013221230A 2012-02-17 2013-02-19 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients Abandoned AU2013221230A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017258955A AU2017258955A1 (en) 2012-02-17 2017-11-10 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
AU2019226190A AU2019226190B2 (en) 2012-02-17 2019-09-05 Methods, compounds and compositions for treatment of influenza and parainfluenza patients

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US61/600,545 2012-02-17
US201261727627P 2012-11-16 2012-11-16
US61/727,627 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017258955A Division AU2017258955A1 (en) 2012-02-17 2017-11-10 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients

Publications (1)

Publication Number Publication Date
AU2013221230A1 true AU2013221230A1 (en) 2014-10-02

Family

ID=48984833

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013221230A Abandoned AU2013221230A1 (en) 2012-02-17 2013-02-19 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
AU2017258955A Abandoned AU2017258955A1 (en) 2012-02-17 2017-11-10 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
AU2019226190A Ceased AU2019226190B2 (en) 2012-02-17 2019-09-05 Methods, compounds and compositions for treatment of influenza and parainfluenza patients

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017258955A Abandoned AU2017258955A1 (en) 2012-02-17 2017-11-10 Methods, compounds and compositions for treatment of parainfluenza virus in immunocompromised patients
AU2019226190A Ceased AU2019226190B2 (en) 2012-02-17 2019-09-05 Methods, compounds and compositions for treatment of influenza and parainfluenza patients

Country Status (9)

Country Link
US (5) US20130280332A1 (https=)
EP (1) EP2841092B1 (https=)
JP (1) JP2015508780A (https=)
CN (2) CN104203267A (https=)
AU (3) AU2013221230A1 (https=)
CA (1) CA2864746A1 (https=)
ES (1) ES2970401T3 (https=)
IL (2) IL234116B (https=)
WO (1) WO2013123521A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
AU2014292888B2 (en) 2013-07-25 2018-03-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
CA2929652A1 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
SG11201607108XA (en) 2014-02-28 2016-09-29 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
KR20170032474A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디히드로프테리디논 유도체 및 그의 용도
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
EP3885343A1 (en) 2014-11-06 2021-09-29 Dana-Farber Cancer Institute, Inc. Indole compounds as ezh2 inhibitors and uses thereof
EP3215160A4 (en) * 2014-11-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20180177852A1 (en) * 2015-06-08 2018-06-28 Ansun Biopharma, Inc. Treatment of human metapneumovirus
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
AU2017252460B2 (en) 2016-04-22 2021-11-18 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
WO2021108462A1 (en) * 2019-11-25 2021-06-03 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
CN1700934B (zh) * 2002-09-06 2011-08-03 菲利普莫里斯美国公司 液体气溶胶制剂和用于制备气溶胶的气溶胶产生装置及方法
WO2004047735A2 (en) 2002-11-22 2004-06-10 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
KR101501780B1 (ko) * 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
JP2013510169A (ja) * 2009-11-06 2013-03-21 ネクスバイオ，インク． 呼吸器管の治療及び予防のための方法、化合物、及び組成物

Also Published As

Publication number Publication date
EP2841092A4 (en) 2015-09-16
ES2970401T3 (es) 2024-05-28
IL234116B (en) 2020-03-31
US20250387457A1 (en) 2025-12-25
AU2019226190B2 (en) 2021-10-07
IL273194B (en) 2022-10-01
JP2015508780A (ja) 2015-03-23
CA2864746A1 (en) 2013-08-22
EP2841092B1 (en) 2023-12-06
HK1207975A1 (en) 2016-02-19
AU2017258955A1 (en) 2017-12-14
WO2013123521A1 (en) 2013-08-22
US20130280332A1 (en) 2013-10-24
EP2841092C0 (en) 2023-12-06
US20210046165A1 (en) 2021-02-18
IL273194B2 (en) 2023-02-01
AU2019226190A1 (en) 2019-09-26
CN109529026A (zh) 2019-03-29
CN104203267A (zh) 2014-12-10
US20150132274A1 (en) 2015-05-14
US20170151315A1 (en) 2017-06-01
EP2841092A1 (en) 2015-03-04
IL273194A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US20250387457A1 (en) Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
US12011453B2 (en) Medicament for prevention or treatment of rhinovirus infection
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
WO2021259195A1 (zh) 治疗新型冠状病毒肺炎的联合用药物
CN111346219A (zh) 干扰素在制备预防冠状病毒感染或预防冠状病毒感染引发的疾病的药物中的用途
EP4232073B1 (en) New dosage regimen for inhaled vasoactive intestinal polypeptide
Nomier et al. Distinctive Therapeutic Strategies against Corona Virus19 (COVID-19): A Pharmacological Review.
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
AU2019389806B2 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
US12083135B2 (en) Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
CN108926707A (zh) Pf4的抗rsv应用
US20230181694A1 (en) Treatment of respiratory viral infections
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
WO2023198757A1 (en) Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
EP4611789A1 (en) Sars-cov-2 binding polypeptide
HK40085702A (en) Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia
WO2024096743A1 (en) Sars-cov-2 binding antibody

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted